# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-22-069017
Filing Date
2022-06-07
Accepted
2022-06-07 17:08:39
Documents
4
Period of Report
2022-08-10

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | tm2217544-1_pre14a.htm | PRE 14A | 656149
2 | GRAPHIC | lg_vynethera-4c.jpg | GRAPHIC | 58250
3 | GRAPHIC | tm2217544d1-px_01vynebw.jpg | GRAPHIC | 818023
4 | GRAPHIC | tm2217544d1-px_02vyne4c.jpg | GRAPHIC | 378124
| Complete submission text file | 0001104659-22-069017.txt |  | 2385167

Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38356 | Film No.: 221001884
SIC: 2834 Pharmaceutical Preparations